Stephen Bloch Sells 111,049 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 111,049 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $71.46, for a total transaction of $7,935,561.54. Following the completion of the sale, the director owned 1,065,135 shares in the company, valued at $76,114,547.10. This represents a 9.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Liquidia Stock Performance

Shares of Liquidia stock traded down $3.88 on Tuesday, hitting $67.92. 2,323,237 shares of the company’s stock were exchanged, compared to its average volume of 1,746,808. The company has a 50-day simple moving average of $50.54 and a 200-day simple moving average of $41.24. The stock has a market capitalization of $6.04 billion, a PE ratio of 485.18 and a beta of 0.57. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $73.22. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business’s quarterly revenue was up 4187.1% compared to the same quarter last year. As a group, equities analysts anticipate that Liquidia Corporation will post 2.97 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on LQDA shares. HC Wainwright lifted their price target on shares of Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, June 5th. Wall Street Zen upgraded shares of Liquidia from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 16th. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. BTIG Research lifted their price target on shares of Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Finally, Wells Fargo & Company raised their price objective on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $60.29.

Institutional Trading of Liquidia

Several institutional investors and hedge funds have recently modified their holdings of LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Liquidia by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after purchasing an additional 1,700 shares during the period. Goldman Sachs Group Inc. increased its holdings in Liquidia by 10.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Liquidia by 15.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares during the last quarter. Creative Planning increased its holdings in Liquidia by 40.7% in the 2nd quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after acquiring an additional 7,765 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in Liquidia by 13.4% in the 2nd quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock valued at $1,174,000 after acquiring an additional 11,111 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).